|
Active substance |
Asfotase alfa |
|
Holder |
Alexion Pharma |
|
Status |
closed |
|
Indication |
long-term enzyme replacement therapy in patients with - hypophosphatasia (HPP) in whom the first symptoms presented before the age of 18, to treat the bone manifestations of the disease |
|
Public documents |
|
|
Last update |
24/10/2024 |
Strensiq®
Last updated on